Constellation Pharmaceuticals (CNST) Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Constellation Pharmaceuticals (CNST) Prices 6.5M Share Common Offering at $34.50/Sh
December 11, 2019 5:57 AM ESTConstellation Pharmaceuticals, Inc., (NASDAQ: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that it has priced an underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $34.50 per share,... More
Constellation Pharmaceuticals (CNST) PT Raised to $55 at Oppenheimer
December 9, 2019 4:21 PM ESTOppenheimer analyst Silvan Tuerkcan raised the price target on Constellation Pharmaceuticals (NASDAQ: CNST) to $55.00 (from $40.00) while maintaining a Outperform rating.
The analyst comments "CNST updated CPI-0610 data with efficacy stable in the key first-line (1L) population (n=15) and excellent tolerability in all settings. SVR35... More
